Table 1.

Trials of tivantinib in treating HCC registered in the - ClinicalTrials.gov.

Clinical Trials ID	Study area	Status	Cancer type, Number of patients	Age (years)	Therapies (Tivantinib)	Time Frame	Responsible Party	Outcomes	Serious Adverse Events (%)
NCT00802555, Phase 1	Multi-center	Completed	Cirrhotic patients with HCC, 21	Over 18	360 mg, BID, Orally	January 2009 to December 2011	Merck Sharp and Dohme	No Results Posted	No Results Posted
NCT00827177, Phase 1	Multi-center	Completed	HCC and other solid tumors, 87	Over 18	360 mg vs 240 mg, BID, Orally	September 2009 to May 2013	Merck Sharp and Dohme	No Results Posted	No Results Posted
NCT01656265, Phase 1	Japan	Completed	Advanced HCC, 24	Over 20	Daily repeating dose of oral Tivantinib (lack of dose), BID, Orally	July 2012 to March 2014	Kyowa Kirin	No Results Posted	No Results Posted
NCT01755767, Phase 3	Multi-center	Completed	MET-high HCC, 383	Over 18	120 mg vs 240 mg vs Placebo, BID, Orally	December 27, 2012 to July 31, 2017	Merck Sharp and Dohme	Median OS: 8.4 (6.8 to 10.0) for Tivantinib vs 9.1 (7.3 to 10.4) for Placebo; Median PFS: 2.1 for Tivantinib and 2.0 for Placebo	Tivantinib 240 mg: 17/28 (60.71%); Tivantinib 120 mg: 103/225 (45.78%)
NCT00988741, Phase 2	USA	Completed	Unresectable HCC, 107	Over 18	360 mg vs 240 mg vs Placebo, BID, Orally	September 2009 to March 2012	Merck Sharp and Dohme	No Results Posted	No Results Posted
NCT02029157, Phase 3	Japan	Completed	MET-high HCC, 386	Over 20	NA	January 2014 to August 2017	Kyowa Kirin	No Results Posted	No Results Posted
NCT01178411, Phase 1	NA	Completed	HCC and other solid tumors, 60	Over 13	360 mg, BID, Orally	August 31, 2010 to January 14, 2019	Merck Sharp and Dohme	NA	19/60 (31.67%)

NA, Not available; HCC, Hepatocellular carcinoma; HR, Hazard ratio; CI, Confidence interval; OS, Overall Survival; PFS, Progress Free Survival.